AEvice Health and THB Global sign MoU to advance remote monitoring of Chronic Respiratory Disease in MENASA region

COVID-19 has disrupted the access to care for many patients globally, with global surveys showing asthma and COPD being among the most impacted chronic conditions in which healthcare resources are reduced due to the pandemic. With travel restrictions, patients are facing difficulties seeking regular treatments for their chronic conditions. While many patients are encouraged to turn to telehealth services to reduce face-to-face interactions, the lack of at-home assessment tools to complement teleconsultations exacerbate existing challenges faced by clinicians in monitoring the symptoms of their patients.

A Connected Device to Enhance Virtual Care for Patients with Chronic Respiratory Disease

The strategic partnership would allow AEvice Health to leverage THB Global’s wide network and strong presence in the MENASA region to distribute their AireSone Device to patients with chronic respiratory disease. The AireSone Device, a non-invasive, wearable respiratory monitor, is capable of monitoring an individual’s respiratory rate, heart rate, and sleep patterns remotely, continuously, and in real-time. When paired with THB Global’s slew of telehealth services, patients can stay more connected to their clinicians by allowing them to remotely monitor their conditions and to track their responses to treatment.

Separately, AEvice Health and THB Global will also collaborate to deploy AEvice Health’s medical device, the AEviceMD, in the MENASA region. With both the AireSone Device and the AEviceMD in the pipeline to be deployed, both companies are determined to advance virtual care for patients with chronic respiratory disease in the long term, enabling them to control their chronic conditions simply and effectively.

Dr Karen Wai, Chief Strategy Officer, AEvice Health, said, “At AEvice Health, we are determined to drive medical innovation to transform healthcare, improve outcomes, and empower lives. This strategic collaboration with THB Global would provide patients suffering from chronic respiratory disease a convenient, efficient, and effective solution to manage their chronic conditions from the comfort of their homes.”

Zarmina Jafar, Head of Strategy, THB Global, said, “Combining innovation with healthcare delivery is an essential part of what we do. The AireSone wearable respiratory monitoring technology compliments our Virtual Hospital and Remote Monitoring services and will have a great impact on the remote Healthcare Management of patients we serve.”

In setting up the partnership between THB Global and AEvice Health, Enterprise Singapore played a significant role in linking both companies up together. Imran Hamsa, Regional Group Director, Middle East & North Africa, Enterprise Singapore, said, “The partnership, facilitated by ESG, between AEvice Health and THB Global will improve patients with chronic respiratory diseases access to medical care in the Middle East, North Africa and South Asia region and allow treatment to continue from home amid the pandemic. We look forward to facilitating more of such partnerships between MedTech companies from Singapore and the United Arab Emirates to drive the development of innovative solutions and support enterprise growth for the long term.”

More information about THB Global and AEvice Health can be found at www.thbglobal.com and www.aevice.com respectively.

About AEvice Health

AEvice Health Pte Ltd is a Singapore-based MedTech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges.

The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the AEvice analytical platform.

In AEvice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives.

More information about the company can be found at www.aevice.com.

About THB Global
The Health Bank (THB) Global is a leading tech-enabled home care, healthcare and chronic disease management company, headquartered in Singapore, with regional offices in Dubai and Karachi. THB Global offers individuals, families, and corporations a variety of virtual hospital services to support and manage their healthcare. With a strong focus on prevention and wellness, we empower our members to be proactive about attaining and maintaining a healthy lifestyle, while preventing illness and disease, through our managed-care, precision medicine, home care and telemonitoring programs.

Our expertise in personalized healthcare delivery offers members and their loved ones peace of mind when facing any chronic or acute healthcare challenge, no matter how complex.

For media enquiries, please contact:
Janelle Low
AEvice Health Pte Ltd
Email: janellelow@aevice.com

Zarmina Jafar
THB Global
Email: zarmina@thbglobal.com

Jiva.AI and Aevice Health Collaborate to Pioneer Breakthrough Medical AI for Asthma Adverse Event Prediction Based on Aevice Health’s FDA-cleared Remote Patient Monitor

 Singapore, London, 2 February 2024 – Jiva.ai, a leading no-code AI platform, and Aevice Health, a prominent provider of remote respiratory monitoring solutions for the healthcare continuum, today announced their collaboration on a jointly funded co-innovation programme by Innovate UK and Enterprise Singapore aimed at creating a state-of-the-art medical AI to predict asthma exacerbations.

The collaboration represents a synergistic blend of Jiva.ai’s cutting-edge AI capabilities and Aevice Health’s expertise in developing a proprietary remote patient monitoring platform that empowers individuals to proactively manage their respiratory health. The project will see the development of an AI capable of asthma exacerbation prediction, utilizing Aevice Health’s FDA-cleared AeviceMD, to provide asthma patients with a groundbreaking tool to take charge of their conditions.

Asthma poses a significant global healthcare burden, with billions spent on reactive management only in the advanced stages. Advancements in remote technology has generated extensive data that holds promise for early asthma prediction and management. Similarly, development in AI technology now offers a possibility to creating diagnostic and prognostic tools that could reduce patient suffering, save lives, and cut costs to healthcare systems.

Implementing a “multimodal AI”, the ability to read multiple different types of data to make predictions, within a clinical setting can be complex. Multimodal AI ideally involves adding new predictors to existing AI models, which is desirable but technologically and logistically difficult in healthcare. With the FDA-cleared AeviceMD, biomarkers of interest for asthma exacerbations can be collected unobtrusively and continuously within and outside of clinical settings. The diverse data collected can then be integrated into the multimodal AI to create an early warning system for asthmatic patients to get the care they need before their asthma escalates.

“Combining Jiva.ai’s no-code AI platform with Aevice Health’s advanced remote patient monitoring platform is a significant leap forward in the realm of healthcare innovation,” said Dr Manish Patel, CEO at Jiva.ai. “We are excited about the potential impact of this collaboration, as it underscores our commitment to leveraging technology to enhance patient outcomes and improve overall healthcare delivery.”

Aevice Health’s CTO, Dr Rex Tan, echoed this sentiment, stating, “Asthma is a global health concern, and our collaboration with Jiva.ai through the Enterprise Singapore and Innovate UK jointly funded co-innovation project aligns with our mission to empower individuals to actively manage their respiratory health.”

This project will leverage the strengths of both companies to develop an intelligent and user-friendly care regime that integrates seamlessly into patients’ lives. The collaboration is set to redefine the landscape of respiratory health management, demonstrating the potential of AI-driven solutions in addressing complex healthcare challenges.

The UK-Singapore Collaborative R&D grant call is a programme jointly launched by Innovate UK, part of the UK Research and Innovation, and Enterprise Singapore. The grant’s objective is to fund business-led collaborative research and development (CR&D) projects between the UK and Singapore, focused on industrial research in particular sectors including health and life sciences.

As the project unfolds, Jiva.ai and Aevice Health anticipate not only advancing the frontiers of medical technology but also making substantial contributions to the broader discourse on harnessing AI for proactive healthcare measures.

About Aevice Health

Aevice Health is a digital health company dedicated to improving asthma and COPD care through its proprietary, non-invasive remote patient monitoring platform and wearable stethoscope, the AeviceMD. Its cutting-edge technology allows for continuous monitoring and real-time disease deterioration tracking, enabling patients to receive personalized care from the comfort of their homes. With actionable insights and effortless treatment response monitoring, healthcare professionals can make timely adjustments for optimized patient outcomes. Aevice Health is on a mission to improve healthcare accessibility, empower patients, and reduce healthcare costs.

More information about the company can be found at www.aevice.com.

About Jiva.AI

Jiva.ai is a leading no-code AI platform that empowers organisations to harness the power of artificial intelligence without the need for extensive coding expertise. With a focus on healthcare, Jiva.ai is committed to driving innovation in the industry and improving patient outcomes through accessible and user-friendly AI solutions.

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com

Sarah D’Souza
Jiva.AI
Email: sarah.dsouza@jiva.ai

Aevice Health Secures US FDA Clearance for Remote Respiratory Monitoring Platform Enabled by Smart Wearable Stethoscope

 Singapore, 20 July 2023 – Aevice Health, a leading provider of remote respiratory monitoring solutions for the healthcare continuum and backed by the Cedars-Sinai Accelerator, today announced that its flagship medical device, the AeviceMD, has received clearance from the U.S. Food and Drug Administration (FDA) as a Class II medical device under the 510(k) route. This clearance empowers the company to market and provide their novel remote monitoring platform to health systems across the country, expanding access to a hassle-free and convenient solution for assessing lung health in clinical and home settings.

The AeviceMD is an integral part of the broader AeviceMD Monitoring System, a comprehensive patient management platform targeted towards chronic respiratory disease management. Leveraging cutting-edge proprietary algorithms, the AeviceMD Monitoring System continuously monitors biomarkers of interest acquired by its smart wearable stethoscope and detects early signs of respiratory exacerbation. The robust platform has completed trials in the emergency department for the analysis of abnormal lung sounds like wheezing against the current standard of care — the clinicians’ own stethoscope-based analysis. The results from these trials are currently being collated and will be disclosed in a separate and forthcoming announcement.

Asthma and COPD, the two most common chronic respiratory diseases, account for over 41 million patients in the US, with authorities expecting the actual prevalence to be higher due to underdiagnosis. These diseases contribute significantly to hospital emergency department visits and readmissions, accounting for over $130B, in direct and indirect costs for the country. Lack of access to post-discharge care and follow-ups are key drivers of the hospitalizations and readmissions.

With the AeviceMD, the clinic can now be brought home. The AeviceMD elevates the ubiquitous stethoscope – an essential tool in every clinic – into a smart, digital, and easily accessible device. Caregivers and patients can simply conduct auscultations using the AeviceMD sensor and conveniently share them with their healthcare professional. Through analysis of these recordings, healthcare providers can accurately identify abnormalities and promptly advise patients, enabling proactive management of lung health.

“This FDA clearance represents a remarkable milestone for our company. While diseases like diabetes or heart failure have seen advancements in technology, there remains a notable lack of comprehensive solutions for respiratory conditions. Unfortunately, the patients requiring these solutions the most are often the ones facing challenges in accessing adequate care. With this clearance, we take a significant stride towards becoming the equivalent of continuous glucose monitors for diabetes, but for respiratory health — a patient-centric, affordable, and accessible solution that empowers patients to achieve a healthy recovery from the comfort of their homes,” said Adrian Ang, CEO of Aevice Health.

As a participant in the Cedars-Sinai Accelerator Class 8, Aevice Health has received invaluable support from the program during its developmental journey in the US. Over the course of the three-month program, the company underwent rigorous mentorship, refining its product-market fit for the US market and strategically shaping its product launch strategy. This was made possible with guidance from clinical key opinion leaders, executive management, operations members of the health system, and investors. As part of their plans, the company is working towards a pilot program with the Cedars-Sinai Medical Center. Additionally, Coronet Ventures, the international Cedars-Sinai organization, has participated in Aevice Health’s bridging round with an undisclosed investment.

2023 has been a momentous year for the AeviceMD thus far. This announcement comes at the heels of the company’s recent Singapore Health Sciences Authority (HSA) first-in-market approval for the AeviceMD Monitoring System in March. Earlier in January, the device was awarded the coveted CES® 2023 Best of Innovation Award in the digital health category, an award recognizing the best of breakthrough technologies improving health equity and saving lives.

This FDA-clearance is the first for the product and paves the way for expanded indications that encompass the full range of features offered by the platform. This includes the AeviceMD Monitoring System’s proprietary lung-sound analyzing algorithm which the company plans to clear in near future.

About Aevice Health

Aevice Health is a digital health company dedicated to improving asthma and COPD care through its proprietary, non-invasive remote patient monitoring platform and wearable stethoscope, the AeviceMD. Its cutting-edge technology allows for continuous monitoring and real-time disease deterioration tracking, enabling patients to receive personalized care from the comfort of their homes. With actionable insights and effortless treatment response monitoring, healthcare professionals can make timely adjustments for optimized patient outcomes. Aevice Health is on a mission to improve healthcare accessibility, empower patients, and reduce healthcare costs.

More information about the company can be found at www.aevice.com.

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com

Aevice Health Receives Singapore HSA Approval for First Smart Wearable Stethoscope in Singapore

 Singapore, 29 March 2023 – Aevice Health, a Singapore-based MedTech company that specializes in developing remote respiratory monitoring solutions, today announced that its flagship medical device, the AeviceMD Monitoring System, has received approval from the Health Sciences Authority of Singapore (HSA). The award-winning patient management platform, powered by a smart wearable stethoscope, is the first of its kind to be made available in Singapore.

The AeviceMD Monitoring System’s wearable stethoscope is one of the smallest globally that can detect abnormal breath sounds, such as wheezing, and monitor vital signs including heart rate and respiratory rate. The device, which is approved for use in patients three years and above, has a unique form factor that allows for continuous and comfortable monitoring across a wide spectrum of ages from young children to the elderly, where respiratory diseases are more prevalent.

Approved for use in both clinical and home settings, the AeviceMD Monitoring System is versatile, providing healthcare professionals with the opportunity to be flexible with the deployment of the device. In-hospital monitoring, hospital-at-home monitoring, and remote monitoring to complement telehealth are just some of the potential use cases.

Chronic respiratory disease affects over 545 million people worldwide and is one of the leading causes of mortality. Asthma and COPD (Chronic Obstructive Pulmonary Disease), which are prevalent in Singapore and many other countries, contribute significantly
to hospital emergency department (ED) visits and readmissions. Early detection of exacerbations can prevent many of these hospitalizations.

The AeviceMD Monitoring System continuously monitors digital biomarkers of interest, providing healthcare professionals with an overview of the patient’s lung health to track progress over time. Patients, who are at risk of exacerbations, can be identified early to prevent readmissions or ED visits.

Adrian Ang, Chief Executive Officer of Aevice Health, said, “This is a momentous milestone for the company and a timely achievement as our pipeline of partnerships in Singapore grows. We are excited to leverage Singapore’s strategic presence in Asia as a medical hub to bring this novel technology into new markets where there is a high prevalence of respiratory diseases.”

With the approval of the AeviceMD Monitoring System, Aevice Health is well-positioned to expand its reach and provide much-needed respiratory monitoring solutions to patients in Singapore and beyond.

About Aevice Health

Aevice Health Pte Ltd is a MedTech company at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges.

The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the Aevice analytical platform.

In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives. More information about the company can be found at www.aevice.com.

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com

Aevice Health Announces the Appointment of David Van Sickle, Former CEO of Propeller Health, as the Board Advisor

Singapore, 15 September 2022 – Aevice Health, a MedTech company developing novel wearables to enable remote management of chronic respiratory diseases, is pleased to announce the appointment of David Van Sickle, PhD, as Strategic Advisor.

Van Sickle, who served as the co-founder and former CEO of Propeller Health, has over 15 years of experience in digital health. As Aevice Health continues to transform the landscape of home management of chronic respiratory diseases such as Asthma and COPD, he will assist the team in developing its US commercialization strategy. Van Sickle will also support the company’s efforts to build clinical evidence for its remote monitoring solutions.

Aevice Health’s flagship device, the AeviceMD, is a wearable stethoscope that allows people to easily record their lung sounds and share them with their physicians. Additionally, the device analyzes the acquired sounds for key respiratory symptoms such as wheezing. From earlier studies done, the company found that clinicians who remotely examine how their patients’ lungs are doing can potentially reduce number of in person visits required to achieve the same clinical outcomes.

“I am thrilled to announce the appointment of David as Strategic Advisor,” said Adrian Ang, Aevice Health CEO. “David’s experience and expertise will be instrumental in helping Aevice Health excel in the US market and beyond. He brought Propeller Health to the global stage and revolutionized the way asthma and COPD are managed. I look forward to his guidance and believe he will serve as a similar catalyst to the growth of Aevice Health.”

While at Propeller Health, a digital health company focused on asthma and COPD medication management, the company secured notable partnerships with many leading pharmaceutical companies, health plans and provider systems. To date, Propeller Health’s connected inhalers have been used by more than 140,000 patients in 16 countries worldwide[1].

Van Sickle led Propeller Health through the 2019 acquisition of the company by ResMed (NYSE: RMD) and continued to run the company as a standalone business until 2021, when he became an Entrepreneur in Residence (EIR) at the San Diego-based medical equipment manufacturer. He was recently appointed Non-Executive Director by Closed Loop Medicine.

“In the US we now have appropriate coding, coverage, and reimbursement to support physicians who remotely monitor their patients with chronic respiratory disease,” said David Van Sickle. “The new wearables from Aevice Health allow easy, accurate, and reliable remote auscultation of lung sounds and enable more informed management of asthma and COPD at home and in the community. I look forward to working with the team to help them bring their wearable sensors to market in the US next year.”

This announcement comes at a momentous time for Aevice Health as the company doubles down on its strategy to scale in its key markets. The company has recently announced its participation in major accelerators in the US and APAC, including the Cedars-Sinai Accelerator and MedTech Innovator APAC. The Cedars-Sinai Accelerator is a 3 month-program that helps position companies for launch in the US market and MedTech Innovator is the largest accelerator for MedTech companies connecting participants with leading players in the MedTech industry.

[1] Propeller Health Fact Sheet (February 2022)

About Aevice Health

Aevice Health Pte Ltd is a MedTech company at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges.

The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the Aevice analytical platform.

In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives. More information about the company can be found at www.aevice.com.

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com